Does $^{18}$F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?

Yuri Cho1, Dong Hyeon Lee1, Yun Bin Lee1, Minjong Lee1, Jeong-ju Yoo1, Won-mook Choi1, Young Youn Cho1, Jin Chul Paeng2, Keon Wook Kang2, June-Key Chung2, Su Jong Yu1, Jeong-Hoon Lee1, Jung-Hwan Yoon1, Hyo-Suk Lee1, Yoon Jun Kim1*

1 Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea, 2 Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Abstract

Background and Aim: The utility of fluorine-18 fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography-computed tomography (PET/CT) in initial staging of hepatocellular carcinoma (HCC) has yet to be fully explored. We assessed the usefulness of $^{18}$F-FDG PET/CT in initial staging of HCC.

Methods: A total of 457 consecutive patients initially diagnosed with HCC at Seoul National University Hospital between 2006 and 2012 were evaluated retrospectively to assess the impact of $^{18}$F-FDG PET/CT on staging and compliance with Milan criteria, relative to dynamic CT of liver and chest x-ray.

Results: Seven among the 457 patients studied showed a shift in Barcelona Clinic Liver Cancer [BCLC] stage (A$ightarrow$C: 6 patients; B$ightarrow$C: 1 patient) and 5 patients who had originally met Milan criteria no longer qualified. $^{18}$F-FDG PET/CT had value in initial staging of early (stage A) or intermediate (stage B) HCC, as determined by dynamic CT of liver and BCLC or AJCC classifications, whereas BCLC stage 0 and stage C tumors were unchanged ($p<0.001$). $^{18}$F-FDG PET/CT disclosed additional metastases in patients with American Joint Committee on Cancer [AJCC] T2 (2.7%), T3a (5.3%), and T3b (4.8%) classifications.

Conclusions: In initial staging of HCC, $^{18}$F-FDG PET/CT provided additional information, impacting the patients with BCLC (stages A and B) and AJCC (T2 and T3) classifications. Its use might be thus appropriate for these patient subsets, especially if hepatic resection or liver transplantation is planned.

Introduction

Hepatocellular carcinoma (HCC) is among the most prevalent cancers worldwide, ranging from 30 per 100,000 population in Southeast Asia to 2 per 100,000 in northern Europe and the United States [1–3], and extrahepatic involvement is not unusual [4,5]. However, newer treatment modalities are currently emerging for those afflicted with HCC [6–8]. When tumor is confined to the liver, aggressive locoregional therapy or liver transplantation (LT) are options, provided the Milan criteria are met. However, when the patients have metastatic HCC, locoregional treatment including LT has limited efficacy [9]. Sorafenib is presently the only treatment with proven survival benefit (relative to best supportive care) in instances of extrahepatic spread [10]. Extrahepatic HCC is thus regarded as systemic disease, with a poor prognosis, and constitutes a contraindication to LT. Hence, the need for accurate staging of HCC, so that treatment may be optimized.

Beyond the liver, HCC frequently involves lungs, abdominal lymph nodes (LN), and bones [11]. Various imaging modalities, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), bone scan, chest x-ray, and angiography, are used in the staging of HCC [12,13]. Although liver dynamic CT and MRI are particularly useful in diagnosing intrahepatic HCC or intra-abdominal lymph node metastases, detection of distant metastases (ie, in brain or bone) can be more problematic [14]. Current guidelines for HCC recommend abdominal dynamic CT or MRI, chest CT, and bone scintigraphy for pre-operative staging [15]. However, the role of PET-based imaging in preoperative testing has yet to be fully explored.

PET using fluorine-18 fluorodeoxyglucose ($^{18}$F-FDG) is a useful tool for detecting distant metastases in other malignancies [16]. Although the role of $^{18}$F-FDG PET in HCC has been investigated to a degree [17,18], the small populations recruited may not be...
had been considered to be treated with transarterial chemoembolization for some patients with aggressive rapid-growing HCC who received percutaneous ethanol injection, radiofrequency ablation or LT), PET/CT was performed for the patients who had been considered for treatment. Therefore, we could not obtain the written informed consents. The data were analyzed anonymously.

Methods

The study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1309-040-519). This study is a retrospective analysis. Various parameters assessed included gender; age; etiology of liver disease; Child-Pugh classification; alpha-fetoprotein (AFP) levels; protein induced by vitamin K antagonist (PIVKA-II) levels; number (single or multiple), shape (nodular or infiltrative), and size (maximum diameter) of primary tumor(s); and presence of portal vein thrombosis.

Statistical Analysis

All analyses were conducted using standard statistical software (SPSS 12.0 for Windows, SPSS Inc, Chicago, IL, USA). Baseline patient clinical parameters were expressed as medians (range) and frequencies. Chi-square and Fisher’s exact tests were used for comparing clinical parameters and tumor characteristics. A two-tailed P-value <0.05 was considered statistically significant.

Results

Baseline Characteristics

Baseline characteristics of the 457 patients are shown in Table 1. Median age was 53.8 years (range, 28–72 years), and 365 patients (79.9%) were male. A majority of the tumors were attributable to hepatitis B virus infection (386, 84.5%). In most patients, liver function and performance status were favorable (Child-Turcotte-Pugh [CTP] class A: 364, 78.3%; ECOG score of 0: 367, 80.3%). Of the 457 patients, 397 (86.9%) had clinical manifestations of liver cirrhosis (LC) including thrombocytopenia, splenomegaly, esophageal/gastric varices, or ascites. All of the patients (n = 25) with chronic hepatitis C infection showed clinical manifestations of LC. Among the patients with chronic hepatitis B infection, 84.5% (326 of 386 patients) showed clinical manifestations of LC at the time of HCC diagnosis. Approximately 72% of the patients (329 of 457 patients) had been under regular surveillance for HCC performing liver ultrasonography or dynamic CT of liver and serum AFP every 6 months due to the high risk factors of HCC (ie, chronic hepatitis B infection, hepatitis C virus [HCV]-related LC, alcoholic LC).

At the time of diagnosis, 237 patients (51.9%) had isolated tumors, whereas in 220 (48.1%), HCC was multifocal. Median tumor size was 4.1 cm (range, 0.8–18 cm), with nodular configurations (93.4%) predominating, and 116 lesions (25.4%) displayed gross vascular invasion. Median serum AFP and PIVKA-II concentrations were 128.7 ng/mL (range, 5–1.7

Impact of 18F-FDG PET/CT on HCC stage

The BCLC and AJCC TNM classifications were assigned before and after 18F-FDG PET/CT, respectively. Lesions on 18F-FDG PET/CT that had gone undetected by dynamic CT of liver and chest x-ray were analyzed relative to BCLC stage, AJCC T classification, and compliancy with Milan criteria. To determine the impact of 18F-FDG PET/CT on treatment decisions, we examined shifts in BCLC stage or compliancy with Milan criteria that would alter patient management.

Various parameters assessed included gender; age; etiology of liver disease; Child-Pugh classification; alpha-fetoprotein (AFP) levels; protein induced by vitamin K antagonist (PIVKA-II) levels; number (single or multiple), shape (nodular or infiltrative), and size (maximum diameter) of primary tumor(s); and presence of portal vein thrombosis.

Metastatic lesions on 18F-FDG PET/CT

Initial 18F-FDG PET/CT findings were abnormal in 219 (47.9%) of the 457 patients. Benign lesions, such as non-specific inflammation, bronchietasis, pneumonia, pulmonary tuberculosis, and bulla, were observed in 174 patients (38.1%), with lung most frequently implicated (55, 12.0%). Other affected sites included LN, bone, gastrointestinal tract, pancreas, thyroid gland, prostate gland, adrenal gland, peritoneal cavity, parotid gland, and spleen (Table 2).

Definitive metastases were observed in 34 patients (7.4%), including 14 lung lesions, eight in LN, and eight bony metastases. Non-definitive, potentially metastatic lesions were identified in 45 (9.8%) patients (lung, 18; LN, 9; bone, 7). Follow-up imaging (within a minimum of 3 months) by chest CT, abdominal CT/ MRI and whole-body bone scan or MRI of bone confirmed extrahepatic metastasis in 10 (22.2%) of these 45 patients. Both
size and number of LNs had increased in two patients, two patients showed lung metastases by chest CT, and positive whole-body bone scan or bone MRI findings were noted in two patients. Of the 79 patients with definitive (n = 34) or potential (n = 45) metastases by initial 18F-FDG PET/CT, 44 patients had true metastatic disease.

On the other hand, of 378 patients with unequivocally normal (n = 238) or benign (n = 140) initial 18F-FDG PET/CT results, only one patient had a verifiable lung metastasis, without a potential or definite lesion on initial 18F-FDG PET/CT. Hence, 45 of the 457 patients had true metastases. In this setting, 18F-FDG PET/CT performance indices were as follows: sensitivity, 0.978 (44/45); specificity, 0.915 (378/413); positive predictive value (PPV), 0.556 (44/79); negative predictive value (NPV), 0.997 (378/379); and accuracy, 0.921 (44 + 378)/(44 + 35 + 1 + 378).

Among the 45 patients with true metastases, 28 patients had extrahepatic disease on dynamic CT of liver, including infradiaphragmatic LN metastases (n = 10), perihepatic only (n = 7) or coexistent with supradiaphragmatic (n = 2) or aortocaval (n = 1) metastases; lung metastases (n = 6); bone metastases (n = 6); and other sites (pancreas, spleen, adrenal gland, peritoneal cavity [n = 6]). In four patients, lung metastases were evident by chest x-ray. In six patients, lung metastases were evident by both liver

Table 1. Baseline characteristics.

| Variables                        | Total (n = 457) |
|----------------------------------|----------------|
| Median age, year (range)         | 53.8 (28–72)  |
| Male sex, n (%)                  | 365 (79.9)     |
| Etiology, n (%)                  | 73 (51.4)      |
| HBV/HCV/alcohol/others           | 386/25/16/30 (84.5/5.5/3.5/6.6) |
| CTP classification, n (%)        | 364/68/25 (78.3/14.6/5.4) |
| A/B/C                            |                |
| ECOG (PST), n (%)                | 367/84/6 (80.3/18.4/1.3) |
| Tumor number, n (%)              |                |
| Single/multiple                  | 237/220 (51.9/48.1) |
| Median tumor size (cm) (range)   | 4.1 (0.8–18)   |
| Tumor type, n (%)                |                |
| Nodular/infiltrative             | 427/30 (93.4/6.6) |
| Vascular tumor invasion, presence, n (%) | 116 (25.4) |
| Portal vein/hepatic vein or IVC/both | 91/10/15 (19.9/8.6/3.3) |
| Median alpha-fetoprotein (ng/mL) (range) | 128.7 (5–1708000) |
| Median PIWKA-II (mAU/mL) (range) | 53.2 (6–48000) |

Abbreviation: CTP, Child-Turcotte-Pugh classification; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; IVC, inferior vena cava; PST, performance status; PIWKA-II, Prothrombin Induced by Vitamin K Antagonist-II.

doi:10.1371/journal.pone.0105679.t001

Table 2. Metastatic lesions observed on 18F-FDG PET/CT.

| Findings on PET/CT                      | Number (n = 457) | %     |
|----------------------------------------|------------------|-------|
| Abnormal lesions, total                | 219              | 47.9  |
|   Definite metastatic lesions          | 34               | 7.4   |
|   Lung/LN/bone/others                  | 14/8/8/4         | 3.1/1.8/1.8/0.9 |
|   Possible metastatic lesions          | 45               | 9.8   |
|   Lung/LN/bone/GI tract/others         | 18/9/7/4/7       | 3.9/2.1/5.0/9.1/1.5 |
|   Definite benign lesions              | 140              | 30.6  |
|   Lung/LN/bone/GI tract/others         | 40/30/23/21/26   | 8.8/6.6/5.4/6.5/7 |
| Final findings, total                  | 219              | 47.9  |
|   Truly metastatic lesions             | 45               | 9.8   |
|   Lung/LN/bone/others                  | 17/12/10/6       | 3.7/2.6/2.2/1.3 |
|   Truly benign lesions                 | 174              | 38.1  |
|   Lung/LN/bone/GI tract/others         | 55/35/28/23/32   | 12/7.7/6.1/5.7 |

Abbreviation: PET/CT, positron emission tomography-computed tomography; LN, lymph node; GI, gastrointestinal.

doi:10.1371/journal.pone.0105679.t002
dynamic CT and chest x-ray. Additional metastases were detected in 7 (1.5%) of the 457 patients by ¹⁸F-FDG PET/CT (Table 3).

### Impact of ¹⁸F-FDG PET/CT on HCC stage

BCLC staging at baseline, prior to ¹⁸F-FDG PET/CT, was as follows: stage 0, 139 (29.9%); stage A, 119 (25.6%); stage B, 71 (15.3%); stage C, 73 (15.7%); and stage D, 55 (11.8%). After ¹⁸F-FDG PET/CT, revisions were as follows: stage 0, 139 (29.9%); stage A, 113 (24.7%); stage B, 70 (15.3%); stage C, 80 (17.5%); and stage D, 55 (11.8%). Seven (1.5%) of the 457 patients showed a shift in BCLC stage from A to C (6/119, 5.0%) and B to C (1/71, 1.4%), whereas none of the patients classified as BCLC stage 0, C, or D disease by dynamic CT of liver showed a shift in BCLC stage after ¹⁸F-FDG PET/CT (P<0.001) (Fig 1).

Prior to ¹⁸F-FDG PET/CT, 163 patients (35.7%) failed to meet Milan criteria. That figure increased to 168 (36.8%) following ¹⁸F-FDG PET/CT evaluations, for a total of 5 additional patients (1.1%) who were deemed ineligible by Milan criteria.

Baseline AJCC staging, prior to ¹⁸F-FDG PET/CT, was as follows: stage I, 206 (44.3%); stage II, 89 (19.1%); stage IIIA, 46 (9.9%); stage IIIB, 23 (4.9%); stage IIIC, 1 (0.2%); stage IVA, 59 (12.7%); and stage IVB, 33 (7.1%). After ¹⁸F-FDG PET/CT, revisions were as follows: stage I, 206 (44.3%); stage II, 89 (19.1%); stage IIIA, 42 (9.2%); stage IIIB, 20 (4.4%); stage IIIC, 1 (0.2%); stage IVA, 62 (13.6%); and stage IVB, 37 (8.1%). Additional metastases were discovered by ¹⁸F-FDG PET/CT in patients with T2 (3/111, 2.7%), T3a (5/57, 5.3%), and T3b (1/21, 4.8%) classifications exclusively, whereas no additional metastases were noted for the patients classified as T1 or T4 (P = 0.04) (Fig 2).

### Table 3. Extrahepatic metastases shown by liver dynamic CT or chest X-ray.

| Images                  | Metastatic lesions on PET/CT (n = 45) |
|-------------------------|---------------------------------------|
| On liver dynamic CT, n (%) | 28 (62.2)                             |
| On chest X-ray, n (%)    | 4 (8.9)                               |
| On both, n (%)           | 6 (13.3)                              |
| Invisible on both, n (%) | 7 (15.6)                              |

Abbreviation: CT, computed tomography; PET, positron emission tomography.

doi:10.1371/journal.pone.0105679.t003

Prior to ¹⁸F-FDG PET/CT, 163 patients (35.7%) failed to meet Milan criteria. That figure increased to 168 (36.8%) following ¹⁸F-FDG PET/CT evaluations, for a total of 5 additional patients (1.1%) who were deemed ineligible by Milan criteria.

Baseline AJCC staging, prior to ¹⁸F-FDG PET/CT, was as follows: stage I, 206 (44.3%); stage II, 89 (19.1%); stage IIIA, 46 (9.9%); stage IIIB, 23 (4.9%); stage IIIC, 1 (0.2%); stage IVA, 59 (12.7%); and stage IVB, 33 (7.1%). After ¹⁸F-FDG PET/CT, revisions were as follows: stage I, 206 (44.3%); stage II, 89 (19.1%); stage IIIA, 42 (9.2%); stage IIIB, 20 (4.4%); stage IIIC, 1 (0.2%); stage IVA, 62 (13.6%); and stage IVB, 37 (8.1%). Additional metastases were discovered by ¹⁸F-FDG PET/CT in patients with T2 (3/111, 2.7%), T3a (5/57, 5.3%), and T3b (1/21, 4.8%) classifications exclusively, whereas no additional metastases were noted for the patients classified as T1 or T4 (P = 0.04) (Fig 2).
After $^{18}$F-FDG PET/CT, the proportions of extrahepatic metastasis according to T classification were as follows: T1, 4/218 (1.8%); T2, 10/111 (9.0%); T3a, 12/57 (21.1%); T3b, 7/21 (33.3%); T4, 12/50 (24.0%).

**Impact of $^{18}$F-FDG PET/CT on HCC treatment**

A total of 7 patients showed shifts in BCLC stage after performing $^{18}$F-FDG PET/CT. Six patients who had been classified as BCLC stage A before $^{18}$F-FDG PET/CT finally turned out to be classified as BCLC stage C due to LN (n = 2), bone (n = 3), and lung (n = 1) metastases after $^{18}$F-FDG PET/CT. Five patients among them were treated with systemic chemotherapy (ie, sorafenib or 5-fluorouracil plus mitomycin) and additional radiotherapy for bone metastasis. Another one patient with lung metastasis was successfully treated with video-assisted thoracoscopic surgery (VATS). A single 0.8 cm-sized round pulmonary nodule had been found in CT imaging, regarded as a benign inflammatory nodule. However after $^{18}$F-FDG PET/CT, lung metastasis was highly suspected because it showed high standardized uptake value (SUV) as high as 7.3. Fine needle biopsy was performed for the nodule. Finally, it turned out to be a true lung metastasis, histologically. After performing VATS, he could undergo living donor LT.

One patient who had been classified as BCLC stage B before $^{18}$F-FDG PET/CT turned out to be classified as BCLC stage C due to LN metastasis after $^{18}$F-FDG PET/CT. Sorafenib was the treatment option for the patient.

**Discussion**

In the initial staging of HCC, $^{18}$F-FDG PET/CT was of benefit for this cohort, impacting those patients with BCLC stage A or B disease and T2 or T3 AJCC classifications. Metastatic lesions by $^{18}$F-FDG PET/CT and not evident by dynamic CT of liver or chest x-ray accounted for 1.5% of patients, resulting in some revisions (BCLC, 1.5%; Milan criteria, 1.1%). $^{18}$F-FDG PET/CT showed a high negative predictive value (99.7%). This is the first large-scale retrospective cohort analysis to evaluate the contribution of $^{18}$F-FDG PET/CT in initial work-up of HCC by tumor staging conventions.

Clinical studies and autopsy findings indicate that extrahepatic metastases are not unusual in patients with HCC. Sites frequently involved are lung (18–53.8%), bone (5.8–38.5%), and LN (26.7–53%). Other potential sites of involvement are adrenal gland, peritoneum, skin, brain, and muscle [11,20]. Locoregional therapies, such as LT, are not indicated in patients with extrahepatic metastases, the latter constituting systemic disease. Precision in staging of HCC is therefore critical for appropriate therapeutic choices, especially if LT is contemplated.

$^{18}$F-FDG-based PET is presently used in other oncologic contexts for diagnostic staging and monitoring of chemotherapeutic efficacy [16,21]. However, the sensitivity of $^{18}$F-FDG PET in primary HCC is very low. Accumulation of FDG in malignant tumors is a function of glucose-6-phosphatase activity, which varies widely for patients with HCC [22]. In an earlier study, $^{18}$F-FDG PET failed to detect primary hepatic malignancy...
and extrahepatic metastasis in liver transplant candidates [23]. 18F-FDG PET may also be superfluous in patients with early-stage HCC, where the incidence and detection rates of extrahepatic metastasis are low [24–27]. Moreover, if extrahepatic metastases are documented by dynamic CT of liver, further delineation by 18F-FDG PET has no effect on choice of treatment.

However, in our study, 7 (1.5%) of the 457 patients assessed by dynamic CT of liver showed a shift in BCLC stage from A to C (6/119, 5.0%) and B to C (1/71, 1.4%), based on 18F-FDG PET/CT results (BCLC stage 0 and stage C tumors were unchanged). Therefore, our findings indicate that 18F-FDG PET/CT has value in initial staging of early (stage A) or intermediate (stage B) HCC, as determined by dynamic CT of liver and BCLC or AJCC classifications.

False-positive accumulation in inflammatory lesions is one limitation of 18F-FDG PET/CT use in the setting of HCC. This is well-known drawback, so caution is needed to avoid erroneous interpretation [28]. Among the 174 truly benign lesions encountered in our study, 34 were initially assessed as definitive (n = 2) or potential (n = 32) metastases by 18F-FDG PET/CT. Nonetheless, recent studies have shown that 18F-FDG PET was useful for tumor characterization and prognostication [29–31]. The maximum SUV correlated inversely with disease-free survival time and recurrence risk [30]. Likewise, tumor progression and aggressiveness of HCC may be extrapolated from PET studies [32,33]. According to reports, poorly differentiated HCC shows greater uptake of 18F-FDG, and a positive correlation between uptake and rapid tumor growth has been demonstrated [34].

Also, clinical studies have reported that PET/CT might be useful in predicting postoperative tumor recurrence and prognosis of the patients with HCC undergoing hepatic resection or LT [35–37]. Therefore, PET/CT might be justified not only for staging shown by this study but also for tumor characterization and prognostication. Especially, initial HCC staging work-ups including PET/CT for extrahepatic lesions should be considered for instances of planned hepatic resection or LT. Add to this our finding that the patients with BCLC stage A and B disease actually benefited from 18F-FDG PET/CT, through discovery of otherwise undetected metastases, then it is only when these patient subsets are destined for surgery or transplantation that the cost of 18F-FDG PET/CT may be justified.

Our study has several limitations. Among the consecutive 457 patients in this study who underwent 18F-FDG PET/CT at the time of HCC diagnosis, many of them had been with early stages (BCLC stage 0 or A) who were considered to be treated with curative modalities including surgical resection and locoregional therapies. Therefore, the number of the patients with advanced stage (BCLC stage C) or end stage (BCLC stage D) included in this study was relatively smaller than that of the patients with early stages, which is a limitation of retrospective cohort study. Moreover, 72% of the patients included in this study had been under regular surveillance for HCC, which might lead to the earlier stages of study subjects. Larger multi-center prospective studies are warranted to confirm these promising results.

In conclusion, our findings indicate that routine staging of HCC (ie, dynamic CT of liver and chest x-ray) gains information from added 18F-FDG PET/CT in patients with BCLC stage A and stage B disease or with AJCC T2 and T3 classifications with a high-negative-predictive value. HCCs at very early stages have low prevalence of extrahepatic metastases, which means that 18F-FDG PET/CT may be unessential for initial staging of patients with very early HCC, in the absence of clinical suspicion for distant metastases with any symptoms or signs. However, 18F-FDG PET/CT has value in initial staging of early (BCLC A) or intermediate HCC (BCLC B), especially if hepatic resection or LT is planned.

**Author Contributions**

Conceived and designed the experiments: YC YJK. Performed the experiments: JCP KWK JKC SJY JHL JHY HSL YJK. Analyzed the data: YC DHL YBL ML JYJ WMC YYC. Contributed reagents/materials/analysis tools: YC DHL YBL. Contributed to the writing of the manuscript: YC YJK.

**References**

1. Haydon GH, Hayes PC (1996) Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 8: 856–860.
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 743–750.
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC (1997) Increase in primary liver cancer in the UK, 1979-94. Lancet 350: 1142-1143.
4. Nakamura T, Okuda K, Kojro M, Jinni A, Yamaguchi R, et al. (1983) Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 51: 863-877.
5. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y (1990) Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 66: 2174–2179.
6. Mazzaferrro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699.
7. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440.
8. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, et al. (2013) Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology.
9. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–1236.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390.
11. Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS, et al. (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216: 698-703.
12. Honda H, Ohnaka H, Murakami J, Kaneko K, Murayama S, et al. (1992) Characteristic findings of hepatocellular carcinoma: an evaluation with comparative study of US, CT, and MRI. Gastrointest Radiol 17: 245–249.
13. Choi D, Kim SH, Lim JH, Cho JM, Lee WJ, et al. (2003) Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 25: 777–785.
14. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr., et al. (1998) Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133: 510-515; discussion 515-516.
15. European Association For The Study Of The Liver, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
16. Iglehart JK (2006) The new era of medical imaging-progress and pitfalls. N Engl J Med 354: 2622–2628.
17. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, et al. (2004) Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31: 1621–1630.
18. Yoon KT, Kim JK, Kim do Y, Ahn SH, Lee JD, et al. (2007) Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 72 Suppl 1: 104–110.
19. Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020–1022.
20. Natsukawa M, Omura T, Akake T, Kuwata Y, Yamazaki K, et al. (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20: 1781–1787.
21. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, et al. (1998) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med Mol Imaging 31: 1621-1630.
22. Okazumi S, Isono K, Endo K, Kikuchi T, Ozaki M, et al. (1992) Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33: 335–339.
23. Tsviey SA, Hildebolt CG, Dehdashti F, Siegel BA, Peters MG, et al. (2003) Detection of primary hepatic malignancy in liver transplant candidates: the role of 18F-FDG PET/CT in initial HCC staging.

**The Role of 18F-FDG PET/CT in Initial HCC Staging**
prospective comparison of CT, MR imaging, US, and PET. Radiology 226: 533–542.

24. Dierckx R, Maes A, Peeters M, Van De Wiele C (2009) FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 53: 336–342.

25. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, et al. (1999) Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94: 3314–3319.

26. Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, et al. (2005) A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 241: 622–628.

27. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, et al. (2004) 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39: 961–968.

28. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23: 1409–1415.

29. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, et al. (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117: 4779–4787.

30. Lee JH, Park JY, Kim do Y, Aha SH, Han KH, et al. (2011) Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 31: 1144–1149.

31. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, et al. (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50: 682–687.

32. Ho CL, Yu SC, Yeung JW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44: 213–221.

33. Yamamoto Y, Nishiyama Y, Kamayama R, Okane K, Kashiwagi H, et al. (2008) Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 49: 1245–1248.

34. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877–1880.

35. Lee SD, Kim SH, Kim YK, Kim C, Kim SK, et al. (2013) 18F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int 26: 50–60.

36. Kim YK, Lee KW, Cho SY, Han SS, Kim SH, et al. (2010) Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16: 767–772.

37. Fartoux I, Balogova S, Nataf V, Kerrou K, Huchet V, et al. (2012) A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nued Med Commun 33: 757–765.